Pharmaceutical Technology

SEPTEMBER 14, 2022

Victoza, Copaxone, Lupron, Zoladex, Sandostatin, and Somatuline are some of the popularly marketed peptide API therapeutic drugs while more than 600 peptide-based pharmacological leads are being investigated worldwide, across various phases of development.

Leads 52

Leads Marketing Pharmacology Retail 52

Pharmaceutical Technology

MAY 15, 2023

Pyridine derivatives contain one nitrogen atom in a six-membered aromatic ring and are the most extensively used heterocycles in the field of drug design, due to their promising effect on pharmacological activity, which has led to the discovery of numerous broad-spectrum therapeutic agents.

Pharmaceutical 52

Pharmaceutical Leads Pharmacology Medicine 52

European Pharmaceutical Review

MAY 2, 2023

Clinical innovation: using digital solutions to deliver the next wave of medicines Strategic collaborations can leverage well-developed infrastructures to develop, manufacture and commercialise medicines in new developing markets, driving a broader distribution of treatments.

Patients 99

Patients Medicine Marketing Medical 99

Evolve Your Success

OCTOBER 24, 2023

I worked at a now-defunct pharmaceutical company in San Diego and did benchtop research in a couple of different pharmacology models for two years. I was happy with the work as far as the pharmacological models that I was responsible for, producing the data for, submitting my papers, and all that stuff at that time.

Sales 64

Sales Medical Manufacturing Medical sales 64

Clarivate

FEBRUARY 28, 2023

The REALITY study conducted in the United States, France, Italy, Spain and the United Kingdom in 2021 reported a distribution of ND4 (61%), ND6 (20%) and ND1 (18%) [6]. Frontiers in Pharmacology; 13:1089033; DOI: 10.3389/fphar.2022.1089033 Globally, ND4 is the most common mutation, followed by ND6 and ND1. ” Ophthalmology; V.127;

Prescription 98

Prescription Patients Pharmacology Healthcare 98

Pharmaceutical Technology

FEBRUARY 13, 2023

By associating molecular properties with in-silico absorption, distribution, metabolism, excretion, and toxicity (ADMET) models, we can significantly increase the robustness of candidate selection, which subsequently reduces the failure rate during clinical trials.

Food and Drug Administration 52

Food and Drug Administration Leads Pharmaceutical Pharmaceutical research 52